Fighting Cancer: From the Bench to Bedside Using Second Generation Cationic Liposomal Therapeutics von Campbell, Robert B., Ying, Bo, Kuesters, Geoffrey M., Hemphill, Ryan

Volltext

Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration von Wang, Qin, Delva, Luisette, Weinreb, Paul H, Pepinsky, Robert B, Graham, Danielle, Veizaj, Elvana, Cheung, Anne E, Chen, Weiping, Nestorov, Ivan, Rohde, Ellen, Caputo, Robin, Kuesters, Geoffrey M, Bohnert, Tonika, Gan, Liang-Shang

Volltext

Abstract CT141: A phase 1 trial of RTX-240, an allogeneic engineered red blood cell with cell -surface expression of 4-1BBL and trans-presented IL-15, in patients with advanced sol... von Hamid, Omid, Luke, Jason, Spira, Alexander, Kuesters, Geoffrey M., Sienczylo, Iga, Gordon, Gilad, Johnson, Melissa L.

Volltext

Importance of the Liposomal Cationic Lipid Content and Type in Tumor Vascular Targeting: Physicochemical Characterization and In Vitro Studies Using Human Primary and Transformed E... von Dabbas, Sudhir, Kaushik, Ritu R., Dandamudi, Suman, Kuesters, Geoffrey M., Campbell, Robert B.

Volltext

Abstract CT187: Phase 1 Trial of RTX-240, allogeneic red blood cells engineered to express 4-1BBL and trans-presented IL-15, in patients (Pts) with advanced solid tumors von Hamid, Omid, Johnson, Melissa L., Luke, Jason, Maziarz, Richard T., Merchan, Jamie, Lim, Emerson E., Patel, Sandip P., Kuesters, Geoffrey M., Sienczylo, Iga, Gordon, Gilad, Campbell, Karen, Horton, Kristin, Turka, Laurence, Spira, Alexander I.

Volltext

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma von De Bacco, Francesca, Orzan, Francesca, Erriquez, Jessica, Casanova, Elena, Barault, Ludovic, Albano, Raffaella, D’Ambrosio, Antonio, Bigatto, Viola, Reato, Gigliola, Patanè, Monica, Pollo, Bianca, Kuesters, Geoffrey, Dell’Aglio, Carmine, Casorzo, Laura, Pellegatta, Serena, Finocchiaro, Gaetano, Comoglio, Paolo M., Boccaccio, Carla

Volltext

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany von Huebner, Hanna, Kurbacher, Christian M, Kuesters, Geoffrey, Hartkopf, Andreas D, Lux, Michael P, Huober, Jens, Volz, Bernhard, Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Häberle, Lothar, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W, Belleville, Erik, Ruebner, Matthias, Untch, Michael, Fasching, Peter A, Janni, Wolfgang, Fehm, Tanja N, Kolberg, Hans-Christian, Wallwiener, Diethelm, Brucker, Sara Y, Schneeweiss, Andreas, Ettl, Johannes

Volltext

Abstract 942: ErbB3 overexpression unleashed by miR-205 epigenetic silencing is a therapeutic target in glioblastoma von De Bacco, Francesca, Orzan, Francesca, Erriquez, Jessica, Casanova, Elena, Barault, Ludovic, Albano, Raffaella, D'Ambrosio, Antonio, Bigatto, Viola, Reato, Gigliola, Patané, Monica, Pollo, Bianca, Kuesters, Geoffrey, Dell'Aglio, Carmine, Casorzo, Laura, Pellegatta, Serena, Finocchiaro, Gaetano, Comoglio, Paolo M., Boccaccio, Carla

Volltext

SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC) von Sequist, Lecia V., Janne, Pasi A., Huber, Rudolf M., Gray, Jhanelle Elaine, Felip, Enriqueta, Perol, Maurice, Hirsch, Fred R., Tan, Daniel Shao-Weng, Kuesters, Geoffrey, Zalutskaya, Alena, Santillana, Sergio, Pipas, J. Marc, Shepherd, Frances A.

Volltext

Heregulin in Germany von Huebner, Hanna, Kurbacher, Christian M, Kuesters, Geoffrey, Hartkopf, Andreas D, Lux, Michael P, Huober, Jens, Volz, Bernhard, Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Häberle, Lothar, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W, Belleville, Erik, Ruebner, Matthias, Untch, Michael, Fasching, Peter A, Janni, Wolfgang, Fehm, Tanja N, Kolberg, Hans-Christian, Wallwiener, Diethelm, Brucker, Sara Y, Schneeweiss, Andreas, Ettl, Johannes

Volltext